Karyopharm Therapeutics Inc.（KPTI）近日宣布，公司计划提交一项补充新药申请（sNDA），旨在推动其核心药物组合——Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化。这一申请将走加速审批通道，寻求监管机构的快速审查与批准。此举标志着Karyopharm在血液肿瘤领域迈出关键一步，尤其针对那些对现有治疗反应不佳的患者群体。
Karyopharm Therapeutics Inc.（KPTI）近日宣布，公司计划提交一项补充新药申请（sNDA），旨在推动其核心药物组合——Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化。这一申请将走加速审批通道，寻求监管机构的快速审查与批准。此举标志着Karyopharm在血液肿瘤领域迈出关键一步，尤其针对那些对现有治疗反应不佳的患者群体。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.